Smartwatch-Triggered Digital Safety Net Trial Opens in Leptomeningeal Metastasis — Can Wearables Predict Neurological Decline and Reduce Hospitalisation?

References

1. 1.Case Comprehensive Cancer Center. (2025). Wearable-triggered digital safety net for real-time monitoring and intervention in leptomeningeal metastasis (NCT07704034). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07704034
2. 2.Dunn, J., Runge, R., & Snyder, M. (2018). Wearables and the medical revolution. Personalized Medicine, 15(5), 429–448. https://doi.org/10.2217/pme-2017-0038
3. 3.Glantz, M. J., Cole, B. F., Glantz, L. K., Cobb, J., Mills, P., Lekos, A., Walters, B. C., & Recht, L. D. (1998). Cerebrospinal fluid cytology in patients with cancer: Minimizing false-negative results. Cancer, 82(8), 1508–1514. https://doi.org/10.1002/(sici)1097-0142(19980415)82:8<1508::aid-cncr17>3.0.co;2-d
4. 4.Husain, M., Colwell, B., & Bhatt, D. L. (2023). Wearable technology in oncology: Current applications and future directions. JAMA Oncology, 9(3), 421–428. https://doi.org/10.1001/jamaoncol.2022.6210
5. 5.Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., Wesseling, P., Rudà, R., & Preusser, M. (2017). EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Annals of Oncology, 28(Suppl. 4), iv84–iv99. https://doi.org/10.1093/annonc/mdx221
6. 6.Nayar, G., Ejikeme, T., Chongsathidkiet, P., Elsamadicy, A. A., Blackwell, K. L., Clarke, J. M., Lad, S. P., & Fecci, P. E. (2017). Leptomeningeal disease: Current diagnostic and therapeutic strategies. Oncotarget, 8(42), 73312–73328. https://doi.org/10.18632/oncotarget.21010